Tasigna (Nilotinib)

The Tasigna (nilotinib) docket, built on claims that this chronic myeloid leukemia medication is linked to accelerated atherosclerosis and related cardiovascular and peripheral-vascular injury, remains a small docket with 36 pending actions roughly five years after centralization. Claimants in this litigation are, by the nature of the underlying disease, already managing a serious cancer diagnosis, and the alleged vascular injury — ranging from peripheral artery disease to more severe cardiovascular or cerebrovascular events — is layered on top of that existing treatment burden, which shapes both the medical record and the damages picture for any individual claim.

For a funder, the modest scale of this docket means opportunities are matter-specific rather than portfolio-scale, and diligence should focus closely on establishing that the alleged vascular injury is attributable to nilotinib treatment rather than to other independent cardiovascular risk factors the claimant may have — a differential-causation question that is central to claim strength in this docket given that leukemia patients often have other treatment-related or pre-existing risk factors for vascular disease.

Medical-lien considerations are meaningful and often complex here, since claimants are typically already receiving extensive oncology treatment, and any vascular-injury-related treatment costs need to be evaluated in that broader treatment context rather than in isolation.

Given the docket's small scale, individual claim evaluation is the appropriate approach rather than portfolio-level inventory finance built for volume this docket does not have. Underwriting timelines here should also account for the added evidentiary work of ruling out competing causes, which can extend the diligence period relative to a docket with a cleaner, single-factor causation story. Criterica Capital's mass-tort finance line, together with medical-lien receivables financing where relevant, applies to claims evaluated on this basis.

Criterica Intelligence's structural brief covers the differential-causation considerations at issue in this docket in more depth.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.